Clinical Trial Update: Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK) [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the safety of BF-200 ALA (Ameluz) for photodynamic therapy in expanded fields of actinic keratosis has been completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• BF-200 ALA (Ameluz) (amelyx? (the active is 5-ALA; brand Ameluz))

Snippet

Sponsor: Biofrontera Bioscience GmbH | Conditions: Actinic Keratoses | Phase 1 | Status: COMPLETED | Results posted: 2021-11-11